Valneva SE
Specialty vaccine company developing and commercializing vaccines for infectious diseases.
VLA | PA
Overview
Corporate Details
- ISIN(s):
- AT0000A10B99 (+3 more)
- LEI:
- 969500DIVIP5VKNW4948
- Country:
- France
- Address:
- 6 RUE ALAIN BOMBARD, 44800 SAINT-HERBLAIN
- Website:
- https://valneva.com/
- Sector:
- Manufacturing
Description
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company has leveraged its expertise to commercialize three vaccines, including a single-shot vaccine for chikungunya. Its research and development pipeline features a broad range of vaccine candidates, including those targeting Lyme disease, Shigella, and Zika.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2013-05-28 10:52 | German | 318.0 KB | |||
| 2013-05-28 09:40 |
Completion of Merger between Vivalis and Intercell to form Valneva
|
English | 417.3 KB | ||
| 2013-05-28 09:40 |
Finalisation du processus de fusion entre Vivalis et Intercell pour former Valn…
|
French | 258.8 KB | ||
| 2013-05-14 08:30 |
Merger between Intercell and Vivalis planned to complete on May 28, 2013
|
English | 204.1 KB | ||
| 2013-05-14 08:30 |
Fusion effective entre Intercell et Vivalis prévue pour le 28 mai 2013
|
French | 125.3 KB | ||
| 2013-05-06 17:40 |
VIVALIS ANNONCE LA SIGNATURE D'UNE NOUVELLE LICENCE DE RECHERCHE AVEC UN LEADER…
|
French | 86.2 KB | ||
| 2013-05-06 17:40 |
VIVALIS ANNOUNCES A NEW EB66® CELL LINE RESEARCH LICENSE AGREEMENT WITH A MAJOR…
|
English | 61.2 KB | ||
| 2013-05-02 18:00 |
VIVALIS : ACTIONS ET DROITS DE VOTE AVRIL 2013
|
French | 133.0 KB | ||
| 2013-05-02 17:45 |
VIVALIS : MISE A DISPOSITION DU DOCUMENT DE REFERENCE 2012
|
French | 167.9 KB | ||
| 2013-04-25 18:05 |
First Quarter 2013 Operating Income Increases 32% to €1.9 million
|
English | 84.9 KB | ||
| 2013-04-25 18:05 |
Produits opérationnels en hausse de 32% à 1,9 M€
|
French | 61.4 KB | ||
| 2013-04-08 17:40 |
VIVALIS ANNOUNCES A NEW EB66® CELL LINE SERVICES AND LICENSE OPTION AGREEMENT …
|
English | 61.4 KB | ||
| 2013-04-08 17:40 |
VIVALIS ANNONCE UN NOUVEL ACCORD DE RECHERCHE AVEC OPTION DE LICENCE AVEC GLAXO…
|
French | 84.2 KB | ||
| 2013-04-04 17:45 |
VIVALIS : ACTIONS ET DROITS DE VOTE MARS 2013
|
English | 132.9 KB | ||
| 2013-04-02 08:03 |
VIVALIS ANNOUNCES THE SUBMISSION OF THE FIRST NEW DRUG APPLICATION FOR AN H5N1 …
|
English | 72.0 KB |
Automate Your Workflow. Get a real-time feed of all Valneva SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Valneva SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Valneva SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-03-18 | N/A | Other | Buy | 44,222 | N/A |
| 2024-01-03 | N/A | Other | Other | 34,802 | N/A |
| 2023-06-20 | N/A | Other | Sell | 192,547 | 1,406,228.50 EUR |
| 2023-06-19 | N/A | Other | Sell | 30,661 | 209,629.26 EUR |
| 2023-06-16 | N/A | Other | Sell | 85,589 | 582,493.06 EUR |
| 2023-06-15 | N/A | Other | Sell | 28,179 | 189,503.78 EUR |
| 2023-06-14 | N/A | Other | Sell | 228,951 | 1,519,914.11 EUR |
| 2023-06-13 | N/A | Other | Sell | 29,401 | 187,922.37 EUR |
| 2023-06-12 | N/A | Other | Sell | 117,854 | 733,782.57 EUR |
| 2023-05-10 | N/A | Other | Buy | 87,523 | N/A |
Peer Companies
